What is the difference between ^18F‑DOPA PET and dopamine transporter (DaT) SPECT scan, and which is the preferred imaging modality for assessing suspected Parkinsonian or movement‑disorder symptoms?

DAT Scan (DaTscan/Ioflupane SPECT) is the Preferred Imaging Modality

For evaluating suspected Parkinsonian syndromes in clinical practice, DAT scan (I-123 ioflupane SPECT) is the preferred and FDA-approved imaging modality over ^18F-DOPA PET. 1

Key Differences Between the Two Scans

What They Measure

• DAT Scan (Ioflupane SPECT): Binds to dopamine transporters on presynaptic dopaminergic neurons, directly measuring the density of these transporters in the striatum 1
• ^18F-DOPA PET: Measures dopamine synthesis capacity by tracking the incorporation of fluorodopa into dopamine production 2

Clinical Performance

DAT scan demonstrates superior sensitivity in early disease:

• In a direct comparison study, DAT-SPECT was abnormal in 7 patients whose ^18F-DOPA PET scans were reported as normal, particularly in clinically uncertain parkinsonian syndrome (CUPS) patients 3
• The striatal loss of FDOPA uptake can be less pronounced than DAT binding loss in early disease stages, making FDOPA-PET interpretation challenging in routine practice 3

Both modalities show excellent diagnostic accuracy when clearly abnormal:

• In established disease, both achieve 100% sensitivity and specificity for distinguishing Parkinson's disease from healthy controls 4
• However, DAT scan's higher sensitivity in early/uncertain cases gives it a clinical advantage 3

Why DAT Scan is Preferred

Regulatory and Practical Advantages

1. FDA-approved for clinical use in the United States 1
2. Widely available with established clinical protocols 5
3. Standardized interpretation criteria with extensive validation 1
4. Earlier detection of dopaminergic dysfunction, including in prodromal stages 5

Diagnostic Utility

A normal DAT scan essentially excludes Parkinsonian syndromes 1, making it invaluable for:

• Differentiating Parkinsonian syndromes (PD, MSA, PSP, CBD) from essential tremor
• Distinguishing neurodegenerative parkinsonism from drug-induced tremor
• Ruling out dopaminergic deficiency in uncertain cases

The scan demonstrates decreased radiotracer uptake in the striatum, typically progressing posterior to anterior (putamen to caudate) 1

When ^18F-DOPA PET May Be Considered

^18F-DOPA PET remains useful in specific scenarios:

• Research settings where dopamine synthesis capacity is the outcome of interest 6
• Monitoring disease progression in established PD 6
• Centers without DAT scan availability where PET infrastructure exists 7

However, the interpretation of FDOPA-PET can be challenging in routine clinical practice, particularly in early disease stages where it may appear falsely normal 3

Important Caveats

Limitations of Both Modalities

• Neither scan differentiates between types of Parkinsonian syndromes (PD vs. MSA vs. PSP vs. CBD) as all show similar patterns of dopaminergic depletion 1, 7
• For distinguishing atypical parkinsonisms from idiopathic PD, FDG-PET or cardiac MIBG scintigraphy provide additional diagnostic information 7

Clinical Algorithm

1. First-line: DAT scan (ioflupane SPECT) for suspected Parkinsonian syndrome
2. If DAT scan is abnormal and atypical features present: Consider FDG-PET to identify metabolic patterns of PSP or other atypical parkinsonisms 1
3. If distinguishing PD from MSA/PSP: Add cardiac MIBG scintigraphy (decreased in PD/DLB, normal in MSA/PSP) 7

Timing Considerations

The median time between scans in comparative studies was 6 months, during which disease progression could account for some discrepancies 3. In rapidly evolving cases, the more sensitive DAT scan provides earlier diagnostic certainty.

The practical reality is that DAT scan's FDA approval, wider availability, superior early detection, and ability to definitively exclude Parkinsonian syndromes when normal make it the clear first choice for clinical decision-making 1, 3, 5.